BioWorld

Jan. 8, 2002

Chiron Buying Matrix For $61M, Adding Tezacitabine To Pipeline

Chiron Corp., its eyes firmly focused on the cancer therapeutic tezacitabine, is acquiring Matrix Pharmaceutical Inc. for $61 million in cash. Read More

Alexion Starts Phase III Study With Heart Drug Pexelizumab

Rodents Modeling Parkinson s Disease Generate Dopaminergic Neurons To Stem Losses In PD

Tripos Collaborates With Pfizer To Help Build Compound Library

Other News To Note

Structural GenomiX Partners With Millennium, Aventis For Discovery

Alteon Raising $18.6M To Fund Discovery, Development Work

Genencor, Seattle Genetics Align To Develop Cancer Therapeutics

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...